LinkedIn Profile

Access Integrated Diagnostics historical Linkedin company profile data on number of followers, employee headcount and more

Records

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:integrateddiagnostics 1655330 Dec 16th, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 16th, 2017 02:21PM Dec 16th, 2017 02:21PM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services
private:integrateddiagnostics 1655330 Dec 17th, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 17th, 2017 08:12AM Dec 17th, 2017 08:12AM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services
private:integrateddiagnostics 1655330 Dec 18th, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 18th, 2017 10:19AM Dec 18th, 2017 10:19AM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services
private:integrateddiagnostics 1655330 Dec 19th, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 19th, 2017 05:03AM Dec 19th, 2017 05:03AM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services
private:integrateddiagnostics 1655330 Dec 21st, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 21st, 2017 12:42PM Dec 21st, 2017 12:42PM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services
private:integrateddiagnostics 1655330 Dec 22nd, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 22nd, 2017 05:53AM Dec 22nd, 2017 05:53AM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services
private:integrateddiagnostics 1655330 Dec 23rd, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 23rd, 2017 09:37AM Dec 23rd, 2017 09:37AM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services
private:integrateddiagnostics 1655330 Dec 24th, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 24th, 2017 01:22PM Dec 24th, 2017 01:22PM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services
private:integrateddiagnostics 1655330 Dec 25th, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 25th, 2017 10:21AM Dec 25th, 2017 10:21AM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services
private:integrateddiagnostics 1655330 Dec 26th, 2017 12:00AM Indi (Integrated Diagnostics) 855 42.00 Open Biotechnology Dec 26th, 2017 07:22AM Dec 26th, 2017 07:22AM Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system. The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com Health Care Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.